What if HIV were unable to develop resistance against a new therapeutic agent?

Abstract excerpt

BACKGROUND: The HIV integrase inhibitor, Dolutegravir (DTG), was recently approved by the Food and Drug Administration in the United States and is the only HIV drug that has not selected for resistance mutations in the clinic when used as part of first-line therapy. This has led to speculation that DTG might have a higher genetic barrier for the development of drug resistance than the other compounds that are...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biochemical and Molecular Research
• Share to HIV/AIDS drug development and treatment
• Share to HIV Research and Treatment